ArticleMycopathologia2025
Trends in Pediatric Invasive Candidiasis: Shifting Species Distribution and Improving Outcomes.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical Utility of the Paed-EQUAL Candida Score in Paediatric Candidemia: A Real-World Cohort Study.Mycoses · 2026Observational
- Clinical Characteristics, Management, and 30-Day Mortality Predictors in an 18-Year Pediatric Candidemia Cohort.Journal of fungi (Basel, Switzerland) · 2026Article
- Irrational and Inappropriate Use of Antifungals in the NICU: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimInvasive candidiasis is a major contributor to morbidity and mortality in hospitalized children, particularly in those with comorbidities or prolonged hospitalizations. This study evaluated the epidemiology, antifungal susceptibility, and outcomes of invasive Candida infections over an 11-year period.
methodsA retrospective study was conducted at Hacettepe University Children's Hospital from 2013 to 2024. Pediatric patients with culture-confirmed invasive Candida infections were included. Data on species distribution, antifungal susceptibility, and clinical outcomes were analyzed.
resultsA total of 158 invasive candidiasis episodes were identified, yielding 166 Candida isolates. Candida albicans was most common (40.3%), followed by Candida parapsilosis SC (24.1%), Nakaseomyces glabratus (7.8%), Candida tropicalis (7.8%), Clavispora lusitaniae (7.2%), and others (12%). Candidemia accounted for 89.9% of cases; less common manifestations included meningitis, peritonitis, endocarditis, and pneumonia. Over time, C. albicans cases declined, while C. parapsilosis SC remained the predominant non-albicans species. Fluconazole resistance was highest in C. parapsilosis SC (13.2%). Overall mortality was 35.4%, with 14.6% directly attributed to invasive candidiasis. Catheter removal significantly reduced mortality (OR = 8.44, 95% CI: 2.81-25.3, p < 0.001).
conclusionsNon-albicans Candida species became increasingly prevalent, while C. albicans declined. Mortality significantly decreased, likely due to improved patient management. Rising azole resistance in C. parapsilosis SC and the benefit of early catheter removal highlight the need for timely, species-specific strategies.
Indexed as
Identifiers
41193764What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.